Rakuten Medical Presented at the 41st Annual J.P. Morgan Healthcare Conference on the Progress of its Pipeline including its Newly Added Antibody-Dye Conjugate RM-0256, Commercial Growth in Japan, and Important Milestones for the Next Few Years

– Leveraging the success in Japan to expand the Alluminox™ platform globally and obtain new approvals as early as 2025 SAN DIEGO, Jan. 30, 2023 /PRNewswire/ — Mickey Mikitani, Co-CEO of Rakuten Medical, Inc. gave a presentation to investors from around the world at the 41st Annual J.P….

Click here to view original post